<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018495</url>
  </required_header>
  <id_info>
    <org_study_id>34812</org_study_id>
    <nct_id>NCT04018495</nct_id>
  </id_info>
  <brief_title>STeP IT UP CF: STimulating ImProved Health And Well-being In CysTic Fibrosis</brief_title>
  <official_title>STimulating ImProved Health And Well-being In CysTic Fibrosis Using Integration Of Fitness Technology and Port CF.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STeP IT UP CF: STimulating ImProved Health And Well-being In CysTic Fibrosis Using
      Integration Of Fitness Technology and Port CF. A pilot in integration of wearable fitness
      tracker data with existing health data provided by CF foundation Patient Registry (Port CF)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants will Consistently Use Fitbit Tracker</measure>
    <time_frame>1 year</time_frame>
    <description>Demonstrate that participants will consistently use and upload data from the fitness tracker as measured by use of at least 20 hours per day and uploading of at least 75% of activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Integration Tool Development</measure>
    <time_frame>1 year</time_frame>
    <description>Develop integration tool for the data from the Fitbit with data from Cystic Fibrosis Foundation Patient Registry.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Trends of FEV1 will be measured</measure>
    <time_frame>1 year</time_frame>
    <description>Analyze the data trends from the Fitbit for activity and sleep with health trends from the CFFPR. Forced Expiratory Volume (FEV1) will be measured pre and post use of Fitbit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Trends of BMI will be measured</measure>
    <time_frame>1 year</time_frame>
    <description>Analyze the data trends from the Fitbit for activity and sleep with health trends from the CFFPR. Body mass index (BMI) per pounds will be measured pre and post Fitbit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Trends exacerbation rates will be measured</measure>
    <time_frame>1 year</time_frame>
    <description>Analyze the data trends from the Fitbit for activity and sleep with health trends from the CFFPR. Exacerbation symptoms and rates will be measured pre and post Fitbit.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Interventional - Fitbit tracker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fitbit Tracker</intervention_name>
    <description>Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness</description>
    <arm_group_label>Interventional - Fitbit tracker</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with Cystic Fibrosis

          -  Age &gt;18, Cystic Fibrosis

        Exclusion Criteria:

          -  A potential subject who meets any of the following exclusion criteria is ineligible to
             participate in the study.

          -  Those unable to commit to at least 3 months follow up for CF care from enrollment at
             study CF center. Inability to speak and understand English.

          -  Those patients without dedicated access to a smartphone, tablet, or computer with
             internet for syncing device and completing patient diary.

          -  Those patients unwilling to sign an informed consent form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rose Franco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeanette Graf, BS</last_name>
    <phone>414-955-6987</phone>
    <email>jgraf@mcw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Hubertz, BS</last_name>
    <phone>414-955-7019</phone>
    <email>ehubertz@mcw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical College of Wisconsin/Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/reporting-and-resources</url>
    <description>Sample size requirements for estimating Pearson, Kendall and Spearman Correlations. Insufficient sleep is a public health problem. Cystic Fibrosis Trust Cystic Fibrosis Registry Report</description>
  </link>
  <reference>
    <citation>Amin R, Bean J, Burklow K, Jeffries J. The relationship between sleep disturbance and pulmonary function in stable pediatric cystic fibrosis patients. Chest. 2005 Sep;128(3):1357-63.</citation>
    <PMID>16162729</PMID>
  </reference>
  <reference>
    <citation>Beattie Z, Oyang Y, Statan A, Ghoreyshi A, Pantelopoulos A, Russell A, Heneghan C. Estimation of sleep stages in a healthy adult population from optical plethysmography and accelerometer signals. Physiol Meas. 2017 Oct 31;38(11):1968-1979. doi: 10.1088/1361-6579/aa9047.</citation>
    <PMID>29087960</PMID>
  </reference>
  <reference>
    <citation>Dancey DR, Tullis ED, Heslegrave R, Thornley K, Hanly PJ. Sleep quality and daytime function in adults with cystic fibrosis and severe lung disease. Eur Respir J. 2002 Mar;19(3):504-10.</citation>
    <PMID>11936530</PMID>
  </reference>
  <reference>
    <citation>de Zambotti M, Baker FC, Colrain IM. Validation of Sleep-Tracking Technology Compared with Polysomnography in Adolescents. Sleep. 2015 Sep 1;38(9):1461-8. doi: 10.5665/sleep.4990.</citation>
    <PMID>26158896</PMID>
  </reference>
  <reference>
    <citation>González-Ortiz M, Martínez-Abundis E, Balcázar-Muñoz BR, Pascoe-González S. Effect of sleep deprivation on insulin sensitivity and cortisol concentration in healthy subjects. Diabetes Nutr Metab. 2000 Apr;13(2):80-3.</citation>
    <PMID>10898125</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Rose Franco</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

